We are live on ! Find out more
XTLB

XTL Biopharmaceuticals
XTLB

4 hedge funds and large institutions have $848K invested in XTL Biopharmaceuticals in 2020 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

33% more funds holding

Funds holding: 3 → 4 (+1)

21% more capital invested

Capital invested by funds: $699K → $848K (+$149K)

0.12% more ownership

Funds ownership: 8.12% → 8.24% (+0.12%)

Holders
4
Holders Change
+1
Holders Change %
+33.33%
% of All Funds
0.08%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
1
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
+$9.71K
2
UBS Group
UBS Group
Switzerland
+$1.8K

Top Sellers

No sellers this quarter

XTLB Hedge Fund Activity: Q3 2020 in Review

4 of the 4,971 institutional investors tracked by Wall St. Rank reported a position in XTL Biopharmaceuticals (XTLB) for Q3 2020, worth a combined $848K — up 21% from $699K a quarter earlier.

Buyers outnumbered sellers: 1 fund opened new XTLB positions and 0 closed out — a net gain of 1 holder — while 1 added to existing stakes and 0 trimmed.

The largest buyer was Morgan Stanley, adding an estimated $9.71K.

  • 4 institutional investors held XTL Biopharmaceuticals (XTLB) as of Q3 2020, up from 3 in Q2 2020.
  • Funds reported $848K of XTL Biopharmaceuticals stock for Q3 2020, up 21% quarter-over-quarter.
  • 1 fund opened new XTL Biopharmaceuticals positions in Q3 2020 and 0 closed out, a net change of +1 holder.
  • The largest XTL Biopharmaceuticals buyer in Q3 2020 was Morgan Stanley, an estimated $9.71K added.

Based on aggregated 13F filings for Q3 2020.